Allarity Therapeutics Stock (NASDAQ:ALLR)
Previous Close
$0.67
52W Range
$0.63 - $283.20
50D Avg
$3.61
200D Avg
$12.79
Market Cap
$11.25M
Avg Vol (3M)
$3.28M
Beta
0.52
Div Yield
-
ALLR Company Profile
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
ALLR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ZURA | Zura Bio Limited |
| ZVSA | ZyVersa Therapeutics, Inc. |
| BDRX | Biodexa Pharmaceuticals Plc |
| VRAX | Virax Biolabs Group Limited |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| CNSP | CNS Pharmaceuticals, Inc. |
| IMMX | Immix Biopharma, Inc. |
| VIRI | Virios Therapeutics, Inc. |
| EFTR | eFFECTOR Therapeutics, Inc. |
| PHIO | Phio Pharmaceuticals Corp. |
| SONN | Sonnet BioTherapeutics Holdings, Inc. |